One Year Exploratory Study to Evaluate the Efficacy and Safety of Belimumab for Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation.

Trial Profile

One Year Exploratory Study to Evaluate the Efficacy and Safety of Belimumab for Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2013 Trial association changed from Human Genome Sciences to GlaxoSmithKline, as Human Genome Sciences acquired by GlaxoSmithKline.
    • 10 Jan 2012 Planned End Date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov record.
    • 10 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top